Lv11
20 积分 2024-04-15 加入
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
1小时前
待确认
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2天前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
2天前
已完结
Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study
13天前
已关闭
Tumor Lysis Syndrome
16天前
已完结
Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?
28天前
已完结
Diffuse großzellige B-Zell-Lymphome und Hodgkin-Lymphome
28天前
已完结
Tumour lysis syndrome: new therapeutic strategies and classification
1个月前
已完结
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
2个月前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
